Amferia Kills Bacteria

Amferia has developed a patented hydrogel platform that stabilizes and delivers antimicrobial peptides (AMPs) to kill bacteria, including antibiotic-resistant strains, through a physical membrane-disruption mechanism. The company's core innovation protects the fragile peptides from enzymatic degradation, enabling sustained antibacterial activity for up to five days. With its first veterinary product launched in Europe and a key FDA De Novo clearance for a human wound dressing, Amferia is transitioning from R&D to commercialization. Its platform has broad potential applications across wound care, surgical coatings, and antimicrobial sprays.

Patented hydrogel platform that stabilizes and delivers antimicrobial peptides (AMPs). The hydrogel protects the peptides from enzymatic degradation, allowing them to selectively bind to and physically disrupt bacterial membranes, killing 99.99% of bacteria (including antibiotic-resistant strains) upon contact without toxicity to human/animal cells.

Amferia competes in the advanced wound care market against large incumbents using silver, iodine, PHMB, and honey-based antimicrobials. Its differentiation is a resistance-breaking physical mechanism and peptide-based technology. In the broader anti-infective coatings space, it would compete with other surface modification technologies and antibiotic coatings.